Synta Pharmaceuticals (NASDAQ:SNTA) will report earnings before markets open on Tuesday, April 30th. Synta Pharmaceuticals Corp. is a biopharmaceutical company developing small-molecule drugs for inflammatory diseases, cancer, and diabetes. The Company has drug candidates in human clinical trials and additional programs in preclinical studies.
Here is your Cheat Sheet to Synta Pharmaceuticals Earnings:
Earnings Expectations: Analysts expect earnings of $-0.27 per share on revenues of $330.00K.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.26 to a loss $0.28. For the current year, the average estimate is a loss of $1.1, which is worse than the estimate ninety days ago.
Here’s how Synta Pharmaceuticals has been performing on an annual basis:
|Revenue ($) in millions||2.62||144.24||14.80||7.58||0.15|
|Diluted EPS ($)||-2.75||2.32||-0.93||-1.00||-1.06|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||3.42||0.15||0.00||0.00||0.00|
|Diluted EPS ($)||-0.2172||-0.27||-0.25||-0.25||-0.2879|
Synta Pharmaceuticals has missed analyst estimates 3 times in the past four quarters. Shareholders could expect a bust if the company misses estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)